Faculty Information - Makoto Okawaki

BooK

Journal

Presentation

（Last updated : 2024-07-29 14:10:21）

Makoto Okawaki
Department Kawasaki Medical School Kawasaki Medical School, Department of Advanced Oncology,

Position Assistant Professor

■ BooK

2011/03

Adoptive Immunotherapy of Cancer Using Autologous Lymphocytes, Cancer Growth and Progression

■ Journal

1.	2023/01/27	Neutrophil-to-lymphocyte Ratio Prior to Each Chemotherapy Line Predicts Clinical Outcomes in Patients With Unresectable Gastric Cancer
2.	2022/02	Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate- Activated Killer (ZAK) Cells – An Analysis for Patients With Incurable Pancreatic Cancer
3.	2022	Advanced gastrointestinal stromal tumor with intracerebral hemorrhage during sunitinib treatment
4.	2022	Severe thrombocytopenia and maculopapular erythema-induced by regorafenib in a patient with advanced gastrointestinal stromal tumor
5.	2021/11	Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
6.	2021/05	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
7.	2020/08/24	Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study
8.	2020/07/29	Metronidazole-Induced Encephalopathy during the Treatment of Advanced Esophageal Squamous Cell Carcinoma
9.	2019/11	Intervention by a palliative care team for patients undergoing allogeneic hematopoietic stem cell transplantation
10.	2015/09	Current Cancer Immunotherapy Using Activated Lymphocytes -Do Lymphocytes Actually Recognize Cancer Cells?
11.	2014/11	Imatinib Plasma Levels during Successful Long-Term Treatment of Metastatic Gastrointestinal Stromal Tumors
12.	2014/06	Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer
13.	2011/07	A case of stroke due to tumor emboli associated with metastatic cardiac liposarcoma
14.	2009/02	Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD2 antibody in adoptive immunotherapy of cancer.
15.	2008/03	Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion
16.	2006/09	Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.
17.	2006/07	Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells.
18.	2005/05	Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
19.	2005/03	HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Display 5 items
Display all(19)

■ Presentation

1.	2023/03/15	Pre-treatment PD-1 lymphocyte ratio in blood may predict clinical outcome of gastric cancer patients under Nivolumab monotherapy （Speech，General）
2.	2022/10/15	Positioning of cancer genomic medicine in colorectal cancer treatment Detection of Aberrant DNA Methylation in Circulating Cell Free DNA to Predict Patients with Col- orectal Cancer （Speech，Panelist at Symposium/Workshop (Applied)）
3.	2022/02/17	Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy （Poster notice，General）
4.	2021/11/12	Validation and development of the diagnostic technology for Lynch syndrome exclusion by a DNA chip detecting MLH1 methylation and BRAF V600E mutations in colorectal cancer （Speech，Panelist at Symposium/Workshop (Applied)）
5.	2019/07/05	Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors （Poster notice，General）
6.	2019/04/01	Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells （Poster notice，General）
7.	2018/11/24	Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer. （Poster notice，General）
8.	2018/11/10	Clinico-pathological features of hypermutant colorectal cancers analyzed over 1000 colorectal cancer （Speech，Panelist at Symposium/Workshop (Other)）
9.	2018/10/22	Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors （Poster notice，General）
10.	2018/10/21	Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients （Poster notice，General）
11.	2017/04/03	Heat shock protein 90 inhibitors suppress PDGFRA reactivation and other receptor tyrosine kinase activation important in drug resistant gastrointestinal stromal tumors. （Poster notice，General）
12.	2016/05/18	HSP90 inhibitor inhibit the activation of multiple kinase pathways and migration of pancreatic cancer cells. （Poster notice，General）
13.	2015/12/20	Imatinib plasma levels and clinical features of successful long-term treatment of metastatic gastrointestinal stromal tumors （Poster notice，General）
14.	2015/12/20	Successful treatment of everolimus for a renal impairment patient with neuroendocrine tumor （Poster notice，General）
15.	2015/04/20	The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma （Poster notice，General）
16.	2014/11/13	Effect of HSP90 inhibitor on proliferation and migration in esophageal squamous cell carcinoma （Speech，General）
17.	2014/09/25	Antitumor effect of HSP90 inhibitor against esophageal cancer （Poster notice，General）
18.	2014/07/17	Clinicopathological study of gastrointestinal neuroendocrine tumor. （Poster notice，General）
19.	2013/02/25	Possibility of combination therapy of molecular targeted drugs for gastrointestinal stromal tumor. （Poster notice，General）
20.	2012/09/20	Antitumor effect of Hsp90 inhibitor in neuroendocrine tumor （Poster notice，General）
21.	2011/07/01	Wnt signaling involved in gastrointestinal neuroendocrine tumors. （Poster notice，General）
22.	2010/09/04	Cancer vaccine in combination with Anti-CD25 antibody for advanced esophageal squamous cell carcinoma. –a case of the prolonged stable disease （Poster notice）
23.	2010/08/25	A case with postoperative bone metastasis of gastrointestinal stromal tumor (GIST) expressing exon 8 mutation of KIT （Poster notice）
24.	2010/08/25	Cancer Vaccine in Combination with Anti-CD25 Antibody for Advanced Esophageal Squamous Cell Carcinomas –A Case of the Prolonged Stable Disease- （Poster notice）
25.	2009/03	Targeting of CD4+CD25high cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer （Poster notice，General）
26.	2005/05/05	CTL induction using cultured dendritic cells and tumor-RNA in gastric cancer
Display 5 items
Display all(26)